217 related articles for article (PubMed ID: 9808499)
21. Population Pharmacokinetics and Bayesian Estimation of the Area Under the Concentration-Time Curve for Ganciclovir in Adult Chinese Renal Allograft Recipients After Valganciclovir Administration.
Chen B; Hu SS; Rui WB; An HM; Zhai XH; Wang XH; Lu JQ; Shao K; Zhou PJ
J Clin Pharmacol; 2021 Mar; 61(3):328-338. PubMed ID: 32926418
[TBL] [Abstract][Full Text] [Related]
22. Ganciclovir pharmacokinetic parameters do not change when extending valganciclovir cytomegalovirus prophylaxis from 100 to 200 days.
Welker H; Farhan M; Humar A; Washington C
Transplantation; 2010 Dec; 90(12):1414-9. PubMed ID: 21076372
[TBL] [Abstract][Full Text] [Related]
23. Establishing pharmacokinetic bioequivalence of valganciclovir oral solution versus the tablet formulation.
Pescovitz MD; Jain A; Robson R; Mulgaonkar S; Freeman R; Bouw MR
Transplant Proc; 2007 Dec; 39(10):3111-6. PubMed ID: 18089334
[TBL] [Abstract][Full Text] [Related]
24. Treatment of active cytomegalovirus disease with oral ganciclovir in renal allograft recipients: monitoring efficacy with quantitative cytomegalovirus polymerase chain reaction.
Jordan SC; Vo A; Bunnapradist S; Toyoda M; Kamil E
Am J Transplant; 2002 Aug; 2(7):671-3. PubMed ID: 12201370
[TBL] [Abstract][Full Text] [Related]
25. Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients.
Vaudry W; Ettenger R; Jara P; Varela-Fascinetto G; Bouw MR; Ives J; Walker R;
Am J Transplant; 2009 Mar; 9(3):636-43. PubMed ID: 19260840
[TBL] [Abstract][Full Text] [Related]
26. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
27. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection.
Tornatore KM; Garey KW; Saigal N; Reed K; Murray B; Ingalls E; DiFrancesco R; Forrest A; Morse G; Venuto R
Clin Transplant; 2001 Oct; 15(5):297-308. PubMed ID: 11678955
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment.
Czock D; Scholle C; Rasche FM; Schaarschmidt D; Keller F
Clin Pharmacol Ther; 2002 Aug; 72(2):142-50. PubMed ID: 12189361
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDS.
Brosgart CL; Louis TA; Hillman DW; Craig CP; Alston B; Fisher E; Abrams DI; Luskin-Hawk RL; Sampson JH; Ward DJ; Thompson MA; Torres RA
AIDS; 1998 Feb; 12(3):269-77. PubMed ID: 9517989
[TBL] [Abstract][Full Text] [Related]
30. Steady-state relative bioavailability of three oral ganciclovir dosage regimens delivering 6,000 mg/day in patients with human immunodeficiency virus.
Jung D; Griffy K; Wong R; Colburn W; Hulse J
J Clin Pharmacol; 1998 Nov; 38(11):1021-4. PubMed ID: 9824783
[TBL] [Abstract][Full Text] [Related]
31. Oral ganciclovir and pharmacokinetics of valganciclovir in liver transplant recipients.
Pescovitz MD
Transpl Infect Dis; 1999; 1 Suppl 1():31-4. PubMed ID: 11565585
[TBL] [Abstract][Full Text] [Related]
32. Oral ganciclovir versus valganciclovir for cytomegalovirus prophylaxis in high-risk liver transplant recipients.
Brady RL; Green K; Frei C; Maxwell P
Transpl Infect Dis; 2009 Apr; 11(2):106-11. PubMed ID: 19054381
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
[TBL] [Abstract][Full Text] [Related]
34. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients.
Pescovitz MD; Rabkin J; Merion RM; Paya CV; Pirsch J; Freeman RB; O'Grady J; Robinson C; To Z; Wren K; Banken L; Buhles W; Brown F
Antimicrob Agents Chemother; 2000 Oct; 44(10):2811-5. PubMed ID: 10991864
[TBL] [Abstract][Full Text] [Related]
35. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.
Badley AD; Seaberg EC; Porayko MK; Wiesner RH; Keating MR; Wilhelm MP; Walker RC; Patel R; Marshall WF; DeBernardi M; Zetterman R; Steers JL; Paya CV
Transplantation; 1997 Jul; 64(1):66-73. PubMed ID: 9233703
[TBL] [Abstract][Full Text] [Related]
36. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
37. Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy.
Turgeon N; Fishman JA; Basgoz N; Tolkoff-Rubin NE; Doran M; Cosimi AB; Rubin RH
Transplantation; 1998 Dec; 66(12):1780-6. PubMed ID: 9884276
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of valganciclovir pharmacokinetics in lung transplant recipients.
Kiser TH; Fish DN; Zamora MR
J Heart Lung Transplant; 2012 Feb; 31(2):159-66. PubMed ID: 22305377
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
[TBL] [Abstract][Full Text] [Related]
40. Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation.
Posadas Salas MA; Taber DJ; Chua E; Pilch N; Chavin K; Thomas B
Transpl Infect Dis; 2013 Dec; 15(6):551-8. PubMed ID: 24010993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
